Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma

Erqi L Pollom1, Timothy T Bui1, Anne Lynn S Chang2

  • 1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.

JAMA Dermatology
|April 16, 2015
PubMed
Summary

The combination of vismodegib and radiotherapy is a feasible and effective treatment for advanced basal cell carcinoma (BCC). This approach showed promising results in patients with recurrent or locally advanced BCC, warranting further investigation.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Cancer Therapies02:49

Cancer Therapies

3.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K